Supported by one trial
One controlled phase 3 trial met its main goal. Confirmed needs a second trial or regulatory approval for this use.
Botulinum toxin type a: improve symptoms or function in MS (type not specified)
Trial timeline
Trial start year. Dot size reflects participants where reported. Only trials that count towards the status are shown.
MS (type not specified) · Spasticity
One controlled phase 3 trial met its main goal. It needs a second trial or regulatory approval to count as confirmed.
- Trials
- 8
- Running now
- 1
- Controlled phase 2/3 trials
- 6
- People in controlled trials
- 823
Deciding trials (phase 3): 1 met, 0 did not.
Other linked trials: 7
Dose comparisons, trials against another medicine, add-on trials, phase 1 and uncontrolled studies. They are listed below but do not set the status.
Trials
Phase 3 · 2016 · Placebo-controlled · MSFT-NCT02660359
Phase 3 · 2016 · Placebo-controlled · MSFT-NCT02660138
- Safety and Efficacy Study of OnabotulinumtoxinA for the Treatment of Urinary Incontinence Due to Neurogenic Detrusor Overactivity (NDO) in Non-Catheterizing Patients With Multiple Sclerosis (MS)decides the statusMet main goal
Phase 3 · 2012 · Placebo-controlled · MSFT-NCT01600716
OnabotulinumtoxinA vs placebo significantly reduced UI at week 6 (-3.3 episodes/day vs -1.1 episodes/day, p < 0.001; primary endpoint).
Read by software from the paper's abstract - A Placebo-Controlled, Randomized, Safety and Efficacy Study of BOTOX® (Botulinum Toxin Type A) Purified Neurotoxin Complex in Patients with Neurogenic Detrusor Overactivity and Neurological Respiratory Impairmentdecides the statusStopped, other reason
Phase 3 · 2007 · Placebo-controlled · MSFT-2006-006299-39
Other linked trials: 7
These linked trials do not set the status.
Phase 3 · 2018 · Not randomised
Phase 3 · 2009 · Not randomised
- Botulinum Toxin Type A for Treating Allodynic Pain in SCI and MSStopped, other reason
Phase 2 · 2013 · Placebo-controlled
Phase 2 · 2011 · Placebo-controlled
The deciding phase and counts come from the Trial Bank’s fixed rules.
Lab evidence
Lab studies in animals or cells. Results in animals often do not hold in people, and these studies never change the status of an idea.
Loading lab studies…
Loading reviews and guidelines…
History
- 2026-11-02Status changed from Confirmed to Supported by one trial
- 2026-10-28First listed as Confirmed
Related hypotheses
- Spasticity: improve symptoms or function in MS (type not specified)
- Arbaclofen: improve symptoms or function in MS (type not specified)
- Baclofen: improve symptoms or function in MS (type not specified)
- Botulinum toxin type a: improve symptoms or function in relapsing and progressive MS
- Cannabidiol: improve symptoms or function in MS (type not specified)
- Dronabinol: improve symptoms or function in MS (type not specified)
- Nabilone: improve symptoms or function in MS (type not specified)
- Nabiximols: improve symptoms or function in MS (type not specified)
- Onabotulinumtoxina: improve symptoms or function in MS (type not specified)
- Rimabotulinumtoxinb: improve symptoms or function in MS (type not specified)
- Tizanidine: improve symptoms or function in MS (type not specified)
Assembled by software from public sources and not checked by people. Each record links to its source. Report an error